
    
      All patients treated with GLYBERA®, in a clinical trial and when GLYBERA® was commercially
      available who are currently participating in the LPLD Registry (Long term follow up of safety
      and efficacy in LPLD), will be asked to continue their participation in this Glybera Registry
      to collect long-term safety and efficacy data.
    
  